| Authors: |
Williams GS; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Mistry B; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Guillard S; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Ulrichsen JC; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Sandercock AM; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Wang J; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK., González-Muñoz A; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Parmentier J; Oncology iMED, AstraZeneca-R&D Boston, Waltham, MA 02451, USA., Black C; MedImmune LLC, Gaithersburg, MD 20878, USA., Soden J; Retrogenix Ltd, Whaley Bridge, High Peak, SK23 7LY, UK., Freeth J; Retrogenix Ltd, Whaley Bridge, High Peak, SK23 7LY, UK., Jovanović J; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Leyland R; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Al-Lamki RS; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK., Leishman AJ; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Rust SJ; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Stewart R; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Jermutus L; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Bradley JR; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK., Bedian V; Oncology iMED, AstraZeneca-R&D Boston, Waltham, MA 02451, USA., Valge-Archer V; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Minter R; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK., Wilkinson RW; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK. |
